No Full Match Donor for AML Bone Marrow Transplant: What Are the Options?
A decision-support guide for AML patients, caregivers, and referring physicians when a fully matched donor cannot be found — and what this means for transplant planning in China.
When a fully HLA-matched donor cannot be identified for a patient with acute myeloid leukemia (AML), transplant planning does not stop. Haploidentical family donors — typically a parent, sibling, or adult child — mismatched unrelated donors, and umbilical cord blood units each represent clinically accepted and increasingly well-studied pathways. For international patients and families navigating this situation, understanding the AML-specific considerations is an important early step.
Key point for families and referring physicians:
The absence of a fully matched donor does not disqualify a patient with AML from receiving an allogeneic stem cell transplant. Haploidentical family donor transplantation, in particular, has become a standard-of-care option at experienced transplant centres — including in China — with outcomes in AML that are broadly comparable to matched unrelated donor transplants in many clinical settings.
Why Bone Marrow Transplant Is Considered in AML
Acute myeloid leukemia is an aggressive blood cancer that originates in the bone marrow. While many patients achieve remission with intensive chemotherapy, AML carries a meaningful risk of relapse — and for patients with intermediate- or high-risk disease, allogeneic stem cell transplantation (also called bone marrow transplant or allo-HSCT) is often recommended during the first or second remission to reduce that risk.
Transplant replaces the patient's blood-forming system with donor cells that are genetically distinct. This creates what is known as a graft-versus-leukemia (GVL) effect — where the donor immune system recognises and attacks residual leukemia cells that chemotherapy alone may not eliminate.
AML situations where transplant is commonly considered:
- Intermediate- or high-risk AML in first complete remission (CR1)
- AML in second complete remission (CR2) after relapse
- AML with high-risk cytogenetics or molecular markers (e.g. FLT3-ITD, TP53, complex karyotype)
- Secondary AML arising from myelodysplastic syndrome (MDS) or prior therapy
- Refractory AML where chemotherapy has not achieved a sustained remission
The decision to proceed with transplant — and the urgency of that decision — depends on the individual patient's AML subtype, remission status, age, and overall fitness. These factors also influence which donor strategy a transplant team is likely to recommend when a perfect match is unavailable.
What "Full Match" Means — and Why a Perfect Donor Is Rare
HLA (human leukocyte antigen) matching is the key compatibility measure in allogeneic transplantation. A fully matched unrelated donor typically shares all 10 critical HLA markers with the patient (10/10 match). A matched sibling donor is an 8/8 match at the most important loci.
Finding a 10/10 matched unrelated donor requires access to a large registry. Global registries — including those in Germany, the United States, China, and elsewhere — together list tens of millions of volunteers, but the probability of finding a full match depends heavily on the patient's ethnic background.
Why patients of non-European ethnicity face longer searches:
- •HLA types vary significantly across ethnic groups, and most large registries have historically been dominated by donors of European ancestry
- •Patients of Asian, Middle Eastern, South Asian, African, or mixed heritage may have a substantially lower probability of finding a full unrelated match within standard search timelines
- •In AML, where timing is clinically important, a prolonged or unsuccessful donor search may itself influence the treatment decision
A matched sibling donor — a brother or sister who shares the same HLA types — is found in only approximately 25–30% of patients. For the majority, a search of unrelated registries is required, and in a meaningful proportion of cases, no adequate matched unrelated donor is identified in time.
Three Accepted Pathways When No Full Match Is Found
When a fully matched sibling or matched unrelated donor is not available, transplant physicians typically evaluate three alternative donor strategies. All three are clinically established; the choice between them depends on individual patient and donor factors.
Haploidentical Family Donor (Half-Match)
A haploidentical donor shares approximately half of the patient's HLA markers. Almost every patient has at least one suitable haploidentical family donor — a parent, sibling, adult child, or sometimes an uncle, aunt, or cousin.
Over the past two decades, outcomes with haploidentical transplantation have improved substantially, largely due to advances in GVHD (graft-versus-host disease) prevention protocols. In AML, published data — including from major Chinese transplant centres using the Beijing Protocol — show that haploidentical transplant outcomes are increasingly comparable to those achieved with matched unrelated donors.
- Key advantage: A suitable donor is almost always available within the immediate family — donor search timelines are not a barrier
- Key consideration: GVHD risk requires careful management; the choice of conditioning and GVHD prophylaxis protocol varies by centre and patient profile
Mismatched Unrelated Donor (9/10 or 8/10 Match)
When a 10/10 matched unrelated donor is not found, some transplant centres will proceed with a donor who is a single-antigen mismatch (9/10) or, less commonly, two-antigen mismatch (8/10). The degree of acceptable mismatch varies by centre protocol, patient age, and urgency.
- Key advantage: May expand the available donor pool from registry searches
- Key consideration: Higher degree of mismatch is associated with increased GVHD and transplant-related mortality risk — the risk-benefit balance requires careful expert evaluation
Umbilical Cord Blood Transplant
Cord blood units stored in public banks can be used when no matched or haploidentical family donor is suitable. Cord blood tolerates a higher degree of HLA mismatch than adult donors and does not require a living donor. However, cord blood transplant is primarily used in smaller patients, as the limited cell dose in a single unit may be insufficient for larger adults.
- Key advantage: Tolerates HLA mismatch; useful when no family donor is available or suitable
- Key consideration: Cell dose constraints limit use in larger adults; engraftment may be slower; less commonly used in AML adults than haplo
AML-Specific Factors That Influence Donor Choice
AML differs from other blood cancers in several ways that directly shape how transplant teams approach the donor shortage situation. Families and referring physicians should be aware of these disease-specific considerations.
Timing and the Remission Window
AML is an aggressive disease. Patients who achieve complete remission after induction chemotherapy are typically in a narrow window during which transplant is most feasible. Prolonged donor searching increases the risk that the disease will relapse before transplant can proceed.
This timing pressure is one reason haploidentical family donor transplant is often preferred when no matched donor is immediately available — a family donor can typically be identified, evaluated, and mobilised significantly faster than completing a global registry search.
Disease Risk Stratification
AML is classified by risk group — typically favourable, intermediate, or high — based on cytogenetics and molecular mutations. Risk group influences the urgency of transplant and, to some extent, the tolerance for donor mismatching.
- ▸High-risk AML: Transplant is generally recommended as soon as CR is achieved; donor availability is a primary concern and often drives the decision toward haplo
- ▸Intermediate-risk AML: Transplant in CR1 is increasingly recommended; the risk-benefit balance of alternative donors is carefully evaluated
- ▸Favourable-risk AML: Transplant in CR1 is not always recommended; a prolonged donor search may be acceptable if chemotherapy consolidation is the planned approach
MRD Status (Minimal Residual Disease)
Measurable residual disease (MRD) — the presence of small numbers of leukemia cells that remain after chemotherapy, detectable only by sensitive molecular or flow cytometry testing — is increasingly used to guide transplant decisions in AML. Patients who are MRD-positive at the time of transplant generally have a higher relapse risk post-transplant. This adds further urgency to proceeding with the best available donor without undue delay.
Haploidentical Transplant for AML: What the Evidence Shows
The evidence base for haploidentical transplantation in AML has grown substantially over the past decade. Several key findings are relevant to patients and families evaluating this option.
Comparable outcomes in AML CR1
Multiple prospective and registry studies — including from Chinese and European transplant groups — have shown that haploidentical transplant outcomes in AML patients in first complete remission are broadly comparable to outcomes with matched unrelated donors, particularly when using post-transplant cyclophosphamide (PTCy) or the Beijing Protocol for GVHD prevention.
GVL effect is preserved
Haploidentical transplants retain the graft-versus-leukemia effect that is central to the anti-leukemia benefit of allogeneic transplantation. In high-risk AML, the immune pressure from a haploidentical graft may in some settings be beneficial.
Donor selection within the family
When multiple family members are available as potential haploidentical donors, transplant teams evaluate several factors including younger donor age, cytomegalovirus (CMV) status, sex matching, and NK cell alloreactivity. The selection process is not simply "any family member" — a structured donor assessment is required.
GVHD remains a key challenge
While GVHD prophylaxis has improved dramatically, graft-versus-host disease — both acute and chronic — remains an important clinical consideration in haploidentical transplantation. The balance between controlling GVHD and preserving the GVL effect is a central management challenge.
Families navigating this decision for an AML patient are encouraged to seek input from transplant specialists who have managed substantial volumes of haploidentical cases in AML specifically — not only general haematology consultation. An online MDT consultation with experienced transplant physicians can help clarify whether haploidentical or another donor strategy is most appropriate for a specific patient's AML profile.
What May Be Different About Haploidentical AML Transplant in China
China has developed one of the world's most extensive haploidentical transplant programmes. This context is relevant for international patients considering transplant coordination in China.
The Beijing Protocol and its evolution
The Beijing Protocol — developed at Peking University People's Hospital under Professor Xiaojun Huang — is one of the most widely adopted haploidentical transplant protocols globally. It uses a combination of ATG (anti-thymocyte globulin), cyclosporine, mycophenolate mofetil, and methotrexate for GVHD prevention, and has been extensively validated in AML across thousands of cases.
Major Chinese transplant centres, including those in Beijing, Shanghai, Hangzhou, and Guangzhou, have accumulated substantial AML-specific haploidentical transplant experience. Published data from these centres form part of the global evidence base that now supports haploidentical transplant as a standard option in AML.
Practical considerations for international AML patients
- Donor mobilisation in China: For international patients who arrive with a family member as their intended donor, the evaluation, mobilisation, and collection process can be coordinated through the transplant centre. Logistics for family members traveling as donors require planning.
- Pre-transplant AML assessment: Chinese transplant centres require a full disease assessment on arrival, including bone marrow evaluation for remission status and MRD testing. Patients who are not in remission at the time of planned transplant may require additional bridging therapy before transplant can proceed.
- Case review before travel: Given the complexity and cost involved, international AML patients are generally advised to arrange a structured medical case review — including their bone marrow biopsy reports, cytogenetics, molecular panel, and treatment history — before committing to travel to China.
For families considering this pathway, our haploidentical transplant resources and cancer treatment coordination service provide further context on how cases are typically structured for international patients.
Supportive Care During AML Transplant in China
Bone marrow transplantation — regardless of donor type — is a demanding process for patients and families. In China, transplant care at major centres is typically delivered alongside structured supportive care approaches.
Integrative supportive care — including elements drawn from Traditional Chinese Medicine such as acupuncture, herbal formulations, and nutritional approaches — may be offered at some centres as a complement to standard transplant care. These approaches are intended to support appetite, manage fatigue, aid sleep, and assist with recovery during and after transplant.
Important to note:
Integrative supportive care is used alongside — not instead of — standard transplant conditioning, GVHD prophylaxis, and post-transplant monitoring. Any supportive care approach is discussed with the transplant team and is not a substitute for evidence-based transplant medicine.
Questions to Ask When No Full Match Is Found for AML
The following questions may help families and referring physicians structure discussions with transplant teams — whether locally or through a structured second opinion.
- 1.What is the patient's AML risk classification, and does this influence the urgency of finding a donor?
- 2.Is the patient currently in complete remission, and what is the MRD status — how does this affect transplant timing?
- 3.Which family members could serve as haploidentical donors, and what evaluation is needed to select the best one?
- 4.Is a mismatched unrelated donor search being conducted in parallel, and on what timeline?
- 5.What GVHD prophylaxis protocol does this centre use for haploidentical AML transplants, and what are the GVHD rates in their published experience?
- 6.What is the centre's experience with haploidentical transplant specifically in AML — not just in mixed leukemia populations?
- 7.If the patient is not currently in remission, what bridging options exist before transplant?
- 8.What are the post-transplant monitoring protocols for AML relapse detection?
How ChinaMed Waypoint Supports AML Transplant Coordination
This article is part of ChinaMed Waypoint's haploidentical transplant resources for international patients and families navigating donor shortage situations, complex transplant decisions, and access to expert review in China. Our resources are designed to support patients, caregivers, and referring physicians — not to replace clinical consultation.
ChinaMed Waypoint is a medical coordination service. We do not provide clinical care or make treatment decisions. What we can support includes:
- Arranging a structured multidisciplinary case review with Chinese transplant specialists experienced in AML and haploidentical transplantation
- Supporting the preparation and translation of medical records for specialist review
- Coordinating logistics for international families and family donors traveling to China for transplant evaluation
- Providing structured information to help families and referring physicians ask better questions and understand the options before committing to a care pathway
Families navigating AML without a full match donor may also find our broader pediatric leukemia and blood disorders resources useful if the patient is a child, or our CAR-T and cell therapy resources relevant if the patient has relapsed or refractory AML being evaluated alongside transplant options.
Frequently Asked Questions
If no full HLA-matched donor is found for AML, is transplant still possible?
Yes. The absence of a fully matched sibling or unrelated donor does not mean transplant is ruled out. Haploidentical family donors, mismatched unrelated donors, and cord blood units are all clinically accepted alternatives used routinely at experienced transplant centres. The choice between these options depends on the individual patient's AML profile, disease status, and available donors.
How quickly does a haploidentical donor need to be identified in AML?
Timing is a critical issue in AML because the disease can relapse between remission and transplant. A haploidentical family donor can typically be identified, evaluated, and prepared for donation significantly faster than completing a global registry search for a matched unrelated donor. This is one of the primary reasons haploidentical transplant is often the preferred pathway when no matched donor is immediately available for an AML patient in remission.
Are haploidentical transplant outcomes in AML acceptable compared with matched donor transplants?
Published evidence — including large registry studies and data from major transplant centres in China and Europe — indicates that haploidentical transplant outcomes in AML patients in first or second complete remission are broadly comparable to those achieved with matched unrelated donors, particularly at experienced centres using well-validated GVHD prevention protocols. Outcomes vary by patient, disease risk, and centre volume, and should be discussed with the treating transplant team.
Can an AML patient receive haploidentical transplant in China if they are an international patient?
Major Chinese transplant centres accept international patients for haploidentical transplant evaluation, including AML patients. A structured medical case review — including bone marrow biopsy, cytogenetics, molecular panel, and full treatment history — is typically required before a centre can assess suitability. Coordination of this process, including document preparation and specialist review, is something ChinaMed Waypoint can support.
What happens if the AML patient is not in remission when no matched donor is found?
Allogeneic transplant — with any donor type — is generally most effective when performed during complete remission. If a patient with AML is not in remission, the transplant team will typically recommend further bridging therapy to achieve remission before proceeding. In some cases, salvage regimens or investigational therapies may be considered. This situation requires urgent specialist consultation, as the options and urgency are highly individual.
Medical Disclaimer: ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice. All treatment decisions — including decisions about transplant timing, donor selection, conditioning regimen, and post-transplant care — should be made in consultation with a qualified haematologist, transplant physician, or relevant specialist with access to the patient's full clinical record.
Request a Structured AML Case Review
If your family is facing AML without a full matched donor — or if you are a referring physician seeking structured specialist input — a multidisciplinary case review with experienced Chinese transplant specialists may help clarify whether haploidentical or another donor strategy is appropriate for your patient's situation.